Key facts
- Sobrera’s last known valuation is $9.0M (Dec 2020).
- It has raised $5.8M; the latest was Later Stage VC ($2.4M) in Feb 2026.
- Notable investors include Alsteron, Byggmastare Anders, Collaxio, Curitas Ventures, GOBIA Enterprises — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Sobrera
- ·The full record, as it builds
Funding rounds
No funding rounds for Sobrera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sobrera
Operator of a biopharmaceutical company intended to offer an effective and easy-to-use treatment for patients with alcohol addiction. The company offers treatment for patients with alcohol addiction to reduce alcohol intake long-term, enabling people to improve their quality of life and reduce the risk of morbidity and premature death as well as the societal costs related to alcohol abuse.
- Sector
- Healthcare
- HQ
- Gothenburg, Sweden
- Founded
- 2019
- Employees
- 5
- Website
- sobrera.com/
- Ownership
- Privately Held (backing)
Sobrera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sobrera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sobrera in its N-PORT filings yet. We sweep new filings monthly.